TECH · NMS · Healthcare
Bio-Techne Corporation
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 14.27
Market price
USD 72.37
Implied upside
-80.3%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Current EV/EBITDA of 30.7x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY27 | FY28 | FY29 | FY30 | FY31 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 1.2bn | USD 1.3bn | USD 1.3bn | USD 1.3bn | USD 1.4bn | +2.2% |
| EBIT | USD 277.1m | USD 283.3m | USD 289.6m | USD 296.1m | USD 302.8m | +2.2% |
| NOPAT | USD 221.4m | USD 226.4m | USD 231.5m | USD 236.7m | USD 242.0m | +2.2% |
| Add depreciation & amortisation | USD 112.1m | USD 114.6m | USD 117.2m | USD 119.8m | USD 122.5m | +2.2% |
| Less capital expenditure | USD -112.1m | USD -114.6m | USD -117.2m | USD -119.8m | USD -122.5m | +2.2% |
| Less increase in working capital | USD 5.2m | USD 5.3m | USD 5.4m | USD 5.6m | USD 5.7m | -2.2% |
| Free cashflow to firm | USD 226.6m | USD 231.7m | USD 236.9m | USD 242.2m | USD 247.7m | +2.2% |
| Discount factor | 0.9478 | 0.8514 | 0.7648 | 0.6870 | 0.6171 | - |
| Present value | USD 214.8m | USD 197.3m | USD 181.2m | USD 166.4m | USD 152.8m | -8.2% |
| Present Value Of The Forecast | USD 912.5m | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.184 | Reported 1.275, pulled toward 1.0 (Blume) |
| Cost of equity | 11.51% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 11.3bn | 97.5% of capital |
| Total debt | USD 289.1m | 2.5% of capital, book value as a proxy |
| Tax rate | 20.1% | Effective, capped at statutory |
| WACC | 11.32% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
60% of EV
- Forecast FCFF, final year
- USD 247.7m
- Capex at depreciation, working capital in reinvestment
- USD 242.0m
- Less reinvestment at g/ROIC (22.1% of NOPAT)
- USD -53.4m
- Capitalised
- USD 188.6m
- ROIC (WACC floor)
- 11.3%
- Terminal value, undiscounted
- USD 2.2bn
- Terminal value, discounted
- USD 1.4bn
- Enterprise value
- USD 2.3bn
- Less net debt
- USD 24.4m
- Equity value
- USD 2.2bn
Exit at 20.0x EBITDA
85% of EV
- Terminal value, undiscounted
- USD 8.5bn
- Terminal value, discounted
- USD 5.2bn
- Enterprise value
- USD 6.2bn
- Less net debt
- USD 24.4m
- Equity value
- USD 6.1bn
Spread between methods: 93%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 9.32% | 17.14 | 17.20 | 17.25 | 17.31 | 17.36 |
| 10.32% | 15.52 | 15.57 | 15.61 | 15.66 | 15.71 |
| 11.32% | 14.18 | 14.22 | 14.27 | 14.31 | 14.35 |
| 12.32% | 13.06 | 13.10 | 13.14 | 13.17 | 13.21 |
| 13.32% | 12.11 | 12.14 | 12.18 | 12.21 | 12.24 |
Outlined: this model. Green text: above today's price of 72.37. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 2.2% | 45.1% | +42.8pp |
| Discount rate | 11.3% | 4.0% | -7.4pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.